市場調査レポート

商品コード

1412804

レノックス・ガストー症候群治療薬市場：治療タイプ、投与経路、流通チャネル、エンドユーザー別- 世界予測2024-2030年

Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Global Forecast 2024-2030

出版日: 2024年01月15日 | 発行: 360iResearch

| ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 754,948円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 913,918円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,072,888円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,390,828円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=158.97円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

レノックス・ガストー症候群治療薬市場規模は2023年に6億4,329万米ドルと推定され、2024年には6億7,063万米ドルに達すると予測され、CAGR 5.28%で2030年には9億2,238万米ドルに達すると予測されます。

レノックス・ガストー症候群治療薬の世界市場

主な市場の統計
基準年【2023年	6億4,329万米ドル
予測年[2024]	6億7,063万米ドル
予測年 [2030]	9億2,238万米ドル
CAGR（%）	5.28%

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはレノックス・ガストー症候群治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、レノックス・ガストー症候群治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-レノックス・ガストー症候群治療薬市場の市場規模および予測は？

2-レノックス・ガストー症候群治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-レノックス・ガストー症候群治療薬市場における技術動向と規制の枠組みは？

4-レノックス・ガストー症候群治療薬市場における主要ベンダーの市場シェアは？

5-レノックス・ガストー症候群治療薬市場への参入に適した形態や戦略的手段は？

市場力学
- 促進要因
  - LGSの危険因子と治療の必要性を抱える人口の増加
  - 政府や世界的組織によるLGSの認識の高まり
  - 希少疾病用医薬品指定の増加
- 抑制要因
  - LGSの診断の限界と高額な治療費
- 機会
  - LGS処理のためのファイトケミカルのイントロダクション
  - LGSの治療における技術の進歩
- 課題
  - 利用可能な治療法に関連する副作用
市場セグメンテーション分析
市場動向分析
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み

第6章レノックス・ガストー症候群治療薬市場治療タイプ別

非外科的治療
- 免疫グロブリン静注療法
- ケトジェニックダイエット製品
手術

第7章レノックス・ガストー症候群治療薬市場：投与経路別

オーラル
非経口

第8章レノックス・ガストー症候群治療薬市場：流通チャネル別

病院薬局
オンライン薬局
小売薬局

第9章レノックス・ガストー症候群治療薬市場：エンドユーザー別

ホームケア
病院
専門クリニック

第10章南北アメリカのレノックス・ガストー症候群治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第11章アジア太平洋地域のレノックス・ガストー症候群治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第12章欧州・中東・アフリカのレノックス・ガストー症候群治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第13章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ主要企業別の分析

第14章競争力のあるポートフォリオ

主要な企業プロファイル
- Abbott Laboratories
- Amneal Pharmaceuticals Inc.
- Aquestive Therapeutics Inc.
- Bausch Health Companies Inc.
- Cision Ltd.
- Eisai Co. Ltd.
- GlaxoSmithKline PLC
- GW Pharmaceuticals PLC
- H. Lundbeck A/S
- Johnson and Johnson
- Lupin Ltd.
- Marinus Pharmaceuticals Inc.
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd
- Supernus Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- Upsher Smith Laboratories LLC
- Viatris Inc.
主要な製品ポートフォリオ

第15章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. LENNOX-GASTAUT SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LENNOX-GASTAUT SYNDROME TREATMENT MARKET DYNAMICS
FIGURE 7. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 8. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
FIGURE 14. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. LENNOX-GASTAUT SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

TABLE 1. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 6. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 8. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY KETOGENIC DIET PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 19. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 38. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 39. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 43. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 44. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 65. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 70. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 71. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 80. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 81. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 90. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 95. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 96. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 100. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 101. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 105. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 110. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 111. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 115. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 127. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 131. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 132. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 136. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 137. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 138. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 142. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 147. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 156. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 157. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 171. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 176. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 177. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 178. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 181. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 182. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 201. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 202. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 211. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 216. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 217. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 218. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 231. LENNOX-GASTAUT SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 232. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 233. LENNOX-GASTAUT SYNDROME TREATMENT MARKET LICENSE & PRICING

Product Code: MRR-742BD518078C

[186 Pages Report] The Lennox-Gastaut Syndrome Treatment Market size was estimated at USD 643.29 million in 2023 and expected to reach USD 670.63 million in 2024, at a CAGR 5.28% to reach USD 922.38 million by 2030.

Global Lennox-Gastaut Syndrome Treatment Market

KEY MARKET STATISTICS
Base Year [2023]	USD 643.29 million
Estimated Year [2024]	USD 670.63 million
Forecast Year [2030]	USD 922.38 million
CAGR (%)	5.28%

Lennox-Gastaut Syndrome Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lennox-Gastaut Syndrome Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lennox-Gastaut Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lennox-Gastaut Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Bausch Health Companies Inc., Cision Ltd., Eisai Co. Ltd., GlaxoSmithKline PLC, GW Pharmaceuticals PLC, H. Lundbeck A/S, Johnson and Johnson, Lupin Ltd., Marinus Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, Upsher Smith Laboratories LLC, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Lennox-Gastaut Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapy Type
- Non-Surgical Treatment
  - Intravenous Immunoglobulin Therapy
  - Ketogenic Diet Products
- Surgery
Route of Administration
- Oral
- Parenteral
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
End Users
- Homecare
- Hospitals
- Specialty Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lennox-Gastaut Syndrome Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lennox-Gastaut Syndrome Treatment Market?

3. What are the technology trends and regulatory frameworks in the Lennox-Gastaut Syndrome Treatment Market?

4. What is the market share of the leading vendors in the Lennox-Gastaut Syndrome Treatment Market?

5. Which modes and strategic moves are suitable for entering the Lennox-Gastaut Syndrome Treatment Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Lennox-Gastaut Syndrome Treatment Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising population with risk factors for LGS and need for treatment
  - 5.1.1.2. Growing awareness of LGS by governments and global organizations
  - 5.1.1.3. Rise in orphan drug designation
- 5.1.2. Restraints
  - 5.1.2.1. Limitations in diagnosing LGS and high cost of treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Introduction of phytochemicals for LGS treatment
  - 5.1.3.2. Technological advancements in the treatment of LGS
- 5.1.4. Challenges
  - 5.1.4.1. Side effects associated with available treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Lennox-Gastaut Syndrome Treatment Market, by Therapy Type

6.1. Introduction
6.2. Non-Surgical Treatment
- 6.3.1. Intravenous Immunoglobulin Therapy
- 6.3.2. Ketogenic Diet Products
6.3. Surgery

7. Lennox-Gastaut Syndrome Treatment Market, by Route of Administration

7.1. Introduction
7.2. Oral
7.3. Parenteral

8. Lennox-Gastaut Syndrome Treatment Market, by Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies

9. Lennox-Gastaut Syndrome Treatment Market, by End Users

9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Specialty Clinics

10. Americas Lennox-Gastaut Syndrome Treatment Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Lennox-Gastaut Syndrome Treatment Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Lennox-Gastaut Syndrome Treatment Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Amneal Pharmaceuticals Inc.
- 14.1.3. Aquestive Therapeutics Inc.
- 14.1.4. Bausch Health Companies Inc.
- 14.1.5. Cision Ltd.
- 14.1.6. Eisai Co. Ltd.
- 14.1.7. GlaxoSmithKline PLC
- 14.1.8. GW Pharmaceuticals PLC
- 14.1.9. H. Lundbeck A/S
- 14.1.10. Johnson and Johnson
- 14.1.11. Lupin Ltd.
- 14.1.12. Marinus Pharmaceuticals Inc.
- 14.1.13. Pfizer Inc.
- 14.1.14. Sanofi SA
- 14.1.15. Sun Pharmaceutical Industries Ltd
- 14.1.16. Supernus Pharmaceuticals Inc.
- 14.1.17. Teva Pharmaceutical Industries Ltd.
- 14.1.18. UCB SA
- 14.1.19. Upsher Smith Laboratories LLC
- 14.1.20. Viatris Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing

レノックス・ガストー症候群治療薬市場：治療タイプ、投与経路、流通チャネル、エンドユーザー別- 世界予測2024-2030年

Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 レノックス・ガストー症候群治療薬市場治療タイプ別

第7章 レノックス・ガストー症候群治療薬市場：投与経路別

第8章 レノックス・ガストー症候群治療薬市場：流通チャネル別

第9章 レノックス・ガストー症候群治療薬市場：エンドユーザー別

第10章 南北アメリカのレノックス・ガストー症候群治療薬市場

第11章 アジア太平洋地域のレノックス・ガストー症候群治療薬市場

第12章 欧州・中東・アフリカのレノックス・ガストー症候群治療薬市場

第13章 競合情勢

第14章 競争力のあるポートフォリオ

第15章 付録